Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Net Income (2020 - 2025)

Historic Net Income for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Mirum Pharmaceuticals' Net Income rose 12040.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 5849.86%. This contributed to the annual value of -$87.9 million for FY2024, which is 4618.49% up from last year.
  • Mirum Pharmaceuticals' Net Income amounted to $2.9 million in Q3 2025, which was up 12040.74% from -$5.9 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Net Income ranged from a high of $57.3 million in Q4 2021 and a low of -$74.0 million during Q2 2023
  • For the 5-year period, Mirum Pharmaceuticals' Net Income averaged around -$25.7 million, with its median value being -$26.9 million (2022).
  • Per our database at Business Quant, Mirum Pharmaceuticals' Net Income surged by 25352.45% in 2021 and then tumbled by 17500.93% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Net Income (Quarter) stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 112.21% to $2.9 million in 2025.
  • Its Net Income was $2.9 million in Q3 2025, compared to -$5.9 million in Q2 2025 and -$14.7 million in Q1 2025.